Regulatory – Page 15 – Alligator Bioscience

2021-08-18

Regulatory

Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company has entered into a research collaboration and license agreem ...

2021-07-13

Regulatory

Positive Phase I data for ATOR-1017 ”As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on ...

2021-06-04

Regulatory

Lund, Sweden, June 4, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today presents novel supportive data from the ongoing Phase I cl ...

2021-04-27

Regulatory

High activity during the first quarter ”So far, 2021 has been characterized by high activity, with a research collaboration that validates o ...

2021-04-22

Regulatory

Ahead of the annual general meeting in Alligator Bioscience AB on June 1, 2021, the Nomination Committee announces its proposals regarding C ...

2021-03-18

Regulatory

Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Board of Directors has appointed Søre ...

2021-03-18

Regulatory

Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2020 has been publi ...

2021-02-26

Regulatory

During February 2021, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of ...

2021-02-26

Regulatory

Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with meta ...